

This report is neither intended to be distributed to Mainland China investors nor to provide securities investment consultancy services within the territory of Mainland China. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan.

01 October 2019

JPM FX - Derivatives Chartpack Notes


More on the interplay between FX betas to global risk factors and pricing parameters

- We extend an earlier framework for assessing the appeal of long/short vol trades based on the relative sensitivities to global market factors and apply similar RV screenings to implied carry and skew.
- The comparison of market betas and implied carry allows highlighting pairs where a positive carry is not offset by a large sensitivity to risk-off factors. A screening of risk-reversals vs sensitivity to global risk factors can allow isolating trade opportunities on dislocated skews.
- Long dated calls on INR still screen favourably based on mild time decay properties and modest sensitivity to risk. In the skew space, we like selling USD/RUB skews, either on a standalone basis or as delta-hedged 1*2 ratio call spread, or vs. a long USD/ZAR risk-reversal as a hedge.

In March we introduced a novel methodology for screening for long/short vol trades based on their sensitivity to a set of global risk-factors ([Beta-over-vol ratios - a bottom-up approach for spotting RV vol trades](#), Ravagli, Jankovic, March 27). Somewhat arbitrarily we focus on four risk factors: S&P, JPM USD trade weighted Index, VIX and VXY-G7. The betas as shown in Exhibit 1 and weekly updated in FX options trading screeners (the latest given [here](#)) represent average of four risk factor betas which express the percentage move in the currency corresponding to the 1-sigma daily moves in the factors. By definition those betas are insensitive to direction, i.e. they are taken in absolute value – as vol is triggered by both up and down moves irrespectively.

Exhibit 1. A linear regression between vol levels (1y ATM) and average betas across a set of USD-pairs. AUD, CAD, PLN, HUF and NZD consistently screen as attractive long-vol opportunities based on the metric.


Average beta represent average of four risk factor betas (in absolute value). 20-year history used in calculating the betas. The risk factors: S&P, JPM USD trade weighted Index, VIX and VXY-G7.



Source: J.P. Morgan


In the following, we expand on the earlier analysis by establishing further comparisons between market betas and pricing parameters like carry (i.e., rates differentials) and skews (i.e., market risk-reversals). One first difference compared to the earlier analysis is that, given the directional nature embedded in the market parameters above, we keep the signs of the regression betas, with positive betas expressing a positive exposure to risk-off factors such as vols and USD Index.

In Exhibit 2 (LHS) we compare such obtained average betas to the level of yearly carry (as implied from the 3M forward). In the chart, for consistency, levels of carry and betas refer to the position long the ccy vs USD (i.e.,



we refer to the ccy/USD convention, regardless of the actual market convention for each pair). The first thing we notice is that level of carry and sign of market betas are negatively correlated, namely positive carry tends to be associated with a negative exposure to risk-off market factors. This result is consistent with an earlier note ([Investigating the interplay between forward points and FX skews](#), Ravagli et al, 22 February) where implied skews were compared to rates differentials: here we look at market betas rather than skews, but the reasoning is very similar (i.e., high-carry currency are typically exposed to risk-off events). The chart can form the basis for a RV screening in the carry vs betas space: one would prefer to own positive carry currencies where the sensitivity to risk-off factors is either positive or at least less negative than on average. Conversely, one would like to sell currencies where carry is negative and market beta is either negative or below a certain average level (for the same level of carry). Two quadrants for buying/selling naturally emerge. Based on the screening, INR, TRY, and RUB are good candidates for long positions vs USD (better than ZAR and BRL for instance). The risk-off nature of the USD despite the higher level of rates than for other developed economies opens the way for several attractive long USD positions, especially against AUD, NZD, NOK, SEK, HUF, PLN. Short EUR/USD and GBP/USD trades are also nicely associated with positive Carry and positive exposure to risk-off factors.

Exhibit 2. RV opportunities in the beta to carry space. Analysis of time decay for long-dated USD crosses favours buying USD/INR and USD/TRY puts and USD/JPY calls.



Source: J.P. Morgan


In an earlier piece we discussed how positive carry can be an offsetting factor massively reducing the time decay suffered by long volatility positions ([Practical recipes for reducing options time decay](#), Ravagli, Jankovic et al, 5 September). In the second chart above, we analyze the scaling properties of fixed strike option premia across different maturities (options correspond to 1y 15% delta calls and puts). From the chart, it is confirmed how USD/INR and USD/TRY puts and USD/JPY calls (especially in the 3y-5y segment) premia suffer a very contained time decay thanks to the positive carry associated with the pairs. Based on the earlier analysis, the modest sensitivity to risk factors of USD/INR should make such long-dated puts attractive: we are keeping a short EUR/INR long-dated put in our model portfolio. While we have focused just on USD-crosses in the charts above, we stress that extending the RV analysis to non-USD crosses would pose no theoretical challenges. Given that supportive carry is a crucial factor for reducing time decay, in this context we would favor holding the positions above without carrying delta-hedging.

As market risk-reversals naturally embody an implied spot/volatility correlation for a given pair, establishing a cross-sectional comparison to risk-off factors can allow highlighting dislocation opportunities suitable for trading. We also stress that for risk-reversals another natural comparison regards the mismatch between implied vs. realized spot/vol correlation, especially as far as the Vanna axis of risk is concerned ([FX options trading screeners](#), Ravagli, 18 September). In Exhibit 3, we plot average risk-factor betas (y-axis) vs. level of implied skew (3m, 25delta, x-axis), by adopting the same conventions as in Exhibit 2: a positive sign for the skew indicates a higher premium for calls over puts for that currency vs. USD. The two quantities are positively correlated on a cross-sectional basis, with a reasonable R² of around 42%.

How can one interpret RV opportunities in this 2-d space? For a given positive level of market risk-reversal, opportunities are found for buying skew on the currencies where average risk-off betas are positive (or above regression values). For the negative skew case, one looks to position for more negative riskies in the case where the average beta is in deep negative territory or below the regression line. We will adhere to market conventions

in the chart by referring to the case where one wants to position for a more negative skew (in case where the latter is negative) as “buying the skew”: as we acknowledge an element of possible confusion here, we will try to eliminate any ambiguity in the following when referring to actual candidate trades. Based on the chart, we see opportunities in buying the skew on JPY (better than CHF), ZAR, BRL, PLN, AUD, NZD. Skew appears overvalued on TRY, RUB, GBP (on the latter case a very well identified skew premium can be attributed to Brexit risk). Such dislocation-based trades would naturally be implemented via delta-hedged risk-reversals.

Exhibit 3. RV opportunities in the betas vs implied skews space. Performance of short USD/RUB skew has been attractive since April 2018 (limit of zero trading costs).



Source: J.P. Morgan

Our EM strategy keeps a constructive view on RUB and especially so against ZAR (see for instance [Emerging Markets Outlook and Strategy](#), Oganes, Goulden, 12 September). The idiosyncratic nature of RUB, other than via the skew premium highlighted above, is also reflected by the low beta to vol ratios of Exhibit 1, which essentially stresses how RUB vol pricing is mostly driven by local than exogenous factors (we recall that Oil is not included amongst the global factors we monitor). These results are broadly consistent with an analysis of EM macro vulnerabilities, which finds Russia near the bottom of the countries examined. With fundamentals (most notably, a currency which remains undervalued) still supportive, and diminished downside risk to lower oil prices, there is potential in fading the rich skew premium highlighted above. RHS above shows how the performance of short skew on USD/RUB (trading daily 3m 25delta riskies, delta hedged with smile-adjusted forwards) has been attractive since Spring 2018, at least by neglecting the impact of trading costs.

We consider:

- *Sell delta-hedged 3m 25delta-hedged risk-reversal on USD/RUB at 2.1/2.6 vols indic.*

Exhibit 4 shows a long term back test of systematically running 1*N ratio call spreads (vega notional) in USD/RUB. The 1*2 ratio call spread structures are efficient in capturing skew underperformance during risk supportive times but are exposed to blowups (left tail risk). The LHS chart of Exhibit 4 shows systematically strong performance outside of the devaluation and sanctions left tail episodes. N=2. i.e. 1*2 vega notional structure is a sweet spot in maximizing the long term Sharpe while keeping net short vol in check. With the supportive macro for RUB and an attractive vol-beta-skew setup at the moment we see RUB as an attractive pocket where one can pick up theta income. Consider:


- *3M delta-hedged USD/RUB 1*2 ratio call spread (ATM/25D) in vega notional @9.8ch against @11.2/11.6 indic.*

Alternatively consider a RUB – ZAR RV trade, supported by the earlier screener on skews:

- *Sell 3M delta-hedged USD/RUB 25D call @11.1/11.7 and hedge it with 3M delta-hedged USD/ZAR 25D call @16.85/17.45, equal vega*

Exhibit 4. 1*2 ratio call spreads offer the sweet spot in maximizing the long term Sharpe while keeping net short vol not overly extended.

Options delta-hedged daily with expiry matched forwards, held for 2-month, 10-yrs history. 0.3vol transaction charge accounted for.



Source: J.P. Morgan

Global Quantitative and Derivatives Strategy

Lorenzo Ravagli, PhD^{AC}

(44-20) 7742-7947

lorenzo.ravagli@jpmorgan.com

J.P. Morgan Securities plc

Global FX Strategy

Ladislav Jankovic^{AC}

(1-212) 834-9618

ladislav.jankovic@jpmchase.com

J.P. Morgan Securities LLC

www.jpmorganmarkets.com

Disclosures

Analyst Certification: All authors named within this report are research analysts unless otherwise specified. The research analyst(s) denoted by an “AC” on the cover of this report certifies (or, where multiple research analysts are primarily responsible for this report, the research analyst denoted by an “AC” on the cover or within the document individually certifies, with respect to each security or issuer that the research analyst covers in this research) that: (1) all of the views expressed in this report accurately reflect the research analyst’s personal views about any and all of the subject securities or issuers; and (2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. For all Korea-based research analysts listed on the front cover, if applicable, they also certify, as per KOFIA requirements, that their analysis was made in good faith and that the views reflect their own opinion, without undue influence or intervention.

Important Disclosures

Company-Specific Disclosures: Important disclosures, including price charts and credit opinion history tables, are available for compendium reports and all J.P. Morgan–covered companies by visiting <https://www.jpm.com/research/disclosures>, calling 1-800-477-0406, or e-mailing research.disclosure.inquiries@jpmorgan.com with your request. J.P. Morgan’s Strategy, Technical, and Quantitative Research teams may screen companies not covered by J.P. Morgan. For important disclosures for these companies, please call 1-800-477-0406 or e-mail research.disclosure.inquiries@jpmorgan.com.

Explanation of Equity Research Ratings, Designations and Analyst(s) Coverage Universe:

J.P. Morgan uses the following rating system: Overweight [Over the next six to twelve months, we expect this stock will outperform the average total return of the stocks in the analyst’s (or the analyst’s team’s) coverage universe.] Neutral [Over the next six to twelve months, we expect this stock will perform in line with the average total return of the stocks in the analyst’s (or the analyst’s team’s) coverage universe.] Underweight [Over the next six to twelve months, we expect this stock will underperform the average total return of the stocks in the analyst’s (or the analyst’s team’s) coverage universe.] Not Rated (NR): J.P. Morgan has removed the rating and, if applicable, the price target, for this stock because of either a lack of a sufficient fundamental basis or for legal, regulatory or policy reasons. The previous rating and, if applicable, the price target, no longer should be relied upon. An NR designation is not a recommendation or a rating. In our Asia (ex-Australia and ex-India) and U.K. small- and mid-cap equity research, each stock’s expected total return is compared to the expected total return of a benchmark country market index, not to those analysts’ coverage universe. If it does not appear in the Important Disclosures section of this report, the certifying analyst’s coverage universe can be found on J.P. Morgan’s research website, www.jpmorganmarkets.com.

J.P. Morgan Equity Research Ratings Distribution, as of July 06, 2019

	Overweight (buy)	Neutral (hold)	Underweight (sell)
J.P. Morgan Global Equity Research Coverage	45%	41%	14%
IB clients*	52%	49%	36%
JPMS Equity Research Coverage	42%	44%	14%
IB clients*	76%	65%	56%

*Percentage of subject companies within each of the "buy," "hold" and "sell" categories for which J.P. Morgan has provided investment banking services within the previous 12 months.

For purposes only of FINRA ratings distribution rules, our Overweight rating falls into a buy rating category; our Neutral rating falls into a hold rating category; and our Underweight rating falls into a sell rating category. Please note that stocks with an NR designation are not included in the table above. This information is current as of the end of the most recent calendar quarter.

Equity Valuation and Risks: For valuation methodology and risks associated with covered companies or price targets for covered companies, please see the most recent company-specific research report at <http://www.jpmorganmarkets.com>, contact the primary analyst or your J.P. Morgan representative, or email research.disclosure.inquiries@jpmorgan.com. For material information about the proprietary models used, please see the Summary of Financials in company-specific research reports and the Company Tearsheets, which are available to download on the company pages of our client website, <http://www.jpmorganmarkets.com>. This report also sets out within it the material underlying assumptions used.

Analysts' Compensation: The research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues.

Registration of non-US Analysts: Unless otherwise noted, the non-US analysts listed on the front of this report are employees of non-US affiliates of J.P. Morgan Securities LLC, may not be registered as research analysts under FINRA rules, may not be associated persons of J.P. Morgan Securities LLC, and may not be subject to FINRA Rule 2241 or 2242 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

Analysts' Compensation: The research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues.

Other Disclosures

J.P. Morgan is a marketing name for investment banking businesses of JPMorgan Chase & Co. and its subsidiaries and affiliates worldwide.

All research reports made available to clients are simultaneously available on our client website, J.P. Morgan Markets. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your sales representative.

Any data discrepancies in this report could be the result of different calculations and/or adjustments.

Any long form nomenclature for references to China; Hong Kong; Taiwan; and Macau within this research report are Mainland China; Hong Kong SAR, China; Taiwan, China; Macau SAR, China.

Options and Futures related research: If the information contained herein regards options or futures related research, such information is available only to persons who have received the proper options or futures risk disclosure documents. Please contact your J.P. Morgan Representative or visit <https://www.theocc.com/components/docs/riskstoc.pdf> for a copy of the Option Clearing Corporation's Characteristics and Risks of Standardized Options or http://www.finra.org/sites/default/files/Security_Futures_Risk_Disclosure_Statement_2018.pdf for a copy of the Security Futures Risk Disclosure Statement.

Principal Trading: J.P. Morgan trades or may trade as principal in the derivatives or the debt securities (or related derivatives) that are the subject of this report.

Private Bank Clients: Where you are receiving research as a client of the private banking businesses offered by JPMorgan Chase & Co. and its subsidiaries ("J.P. Morgan Private Bank"), research is provided to you by J.P. Morgan Private Bank and not by any other division of J.P. Morgan, including but not limited to the J.P. Morgan corporate and investment bank and its research division.

Legal entity responsible for the production of research: The legal entity identified below the name of the Reg AC research analyst who authored this report is the legal entity responsible for the production of this research. Where multiple Reg AC research analysts authored this report with different legal entities identified below their names, these legal entities are jointly responsible for the production of this research.

Legal Entities Disclosures

U.S.: JPMS is a member of NYSE, FINRA, SIPC and the NFA. JPMorgan Chase Bank, N.A. is a member of FDIC. **Canada:** J.P. Morgan Securities Canada Inc. is a registered investment dealer, regulated by the Investment Industry Regulatory Organization of Canada and the Ontario Securities Commission and is the participating member on Canadian exchanges. **U.K.:** JPMorgan Chase N.A., London Branch, is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and to limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from J.P. Morgan on request. J.P. Morgan Securities plc (JPMS plc) is a member of the London Stock Exchange and is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. Registered in England & Wales No. 2711006. Registered Office 25 Bank Street, London, E14 5JP.

Germany: This material is distributed in Germany by J.P. Morgan Securities plc, Frankfurt Branch which is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht and also by J.P. Morgan AG (JPM AG) which is a member of the Frankfurt stock exchange and is regulated by the Federal Financial Supervisory Authority (BaFin), JPM AG is a company incorporated in the Federal Republic of Germany with registered office at Taunustor 1, 60310 Frankfurt am Main, the Federal Republic of Germany. **South Africa:** J.P. Morgan Equities South Africa Proprietary Limited is a member of the Johannesburg Securities Exchange and is regulated by the Financial Services Board. **Hong Kong:** J.P. Morgan Securities (Asia Pacific) Limited (CE number AAJ321) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission in Hong Kong and/or J.P. Morgan Broking (Hong Kong) Limited (CE number AAB027) is regulated by the Securities and Futures Commission in Hong Kong. J.P. Morgan Chase Bank, N.A., Hong Kong is organized under the laws of U.S.A. with limited liability. **Korea:** This material is issued and distributed in Korea by or through J.P. Morgan Securities (Far East) Limited, Seoul Branch, which is a member of the Korea Exchange(KRX) and is regulated by the Financial Services Commission (FSC) and the Financial Supervisory Service (FSS). **Australia:** J.P. Morgan Securities Australia Limited (JPMSAL) (ABN 61 003 245 234/AFS Licence No: 238066) is regulated by ASIC and is a Market, Clearing and Settlement Participant of ASX Limited and CHI-X. **Taiwan:** J.P. Morgan Securities (Taiwan) Limited is a participant of the Taiwan Stock Exchange (company-type) and regulated by the Taiwan Securities and Futures Bureau. **India:** J.P. Morgan India Private Limited (Corporate Identity Number - U67120MH1992FTC068724), having its registered office at J.P. Morgan Tower, Off. C.S.T. Road, Kalina, Santacruz - East, Mumbai – 400098, is registered with Securities and Exchange Board of India (SEBI) as a 'Research Analyst' having registration number INH000001873. J.P. Morgan India Private Limited is also registered with SEBI as a member of the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited (SEBI Registration Number – INZ000239730) and as a Merchant Banker (SEBI Registration Number - MB/INM000002970). Telephone: 91-22-6157 3000, Facsimile: 91-22-6157 3990 and Website: www.jpmipl.com. For non local research reports, this material is not distributed in India by J.P. Morgan India Private Limited. **Thailand:** This material is issued and distributed in Thailand by JPMorgan Securities (Thailand) Ltd., which is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission and its registered address is 3rd Floor, 20 North Sathorn Road, Silom, Bangrak, Bangkok 10500. **Indonesia:** PT J.P. Morgan Sekuritas Indonesia is a member of the Indonesia Stock Exchange and is regulated by the OJK a.k.a. BAPEPAM LK. **Philippines:** J.P. Morgan Securities Philippines Inc. is a Trading Participant of the Philippine Stock Exchange and a member of the Securities Clearing Corporation of the Philippines and the Securities Investor Protection Fund. It is regulated by the Securities and Exchange Commission. **Brazil:** Banco J.P. Morgan S.A. is regulated by the Comissão de Valores Mobiliários (CVM) and by the Central Bank of Brazil. **Mexico:** J.P. Morgan Casa de Bolsa, S.A. de C.V., J.P. Morgan Grupo Financiero is a member of the Mexican Stock Exchange and authorized to act as a broker dealer by the National Banking and Securities Exchange Commission. **Singapore:** This material is issued and distributed in Singapore by or through J.P. Morgan Securities Singapore Private Limited (JPMSS) [MCI (P) 058/04/2019 and Co. Reg. No.: 199405335R], which is a member of the Singapore Exchange Securities Trading Limited and/or JPMorgan Chase Bank, N.A., Singapore branch (JPMCB Singapore) [MCI (P) 070/09/2019], both of which are regulated by the Monetary Authority of Singapore. This material is issued and distributed in Singapore only to accredited investors, expert investors and institutional investors, as defined in Section 4A of the Securities and Futures Act, Cap. 289 (SFA). This material is not intended to be issued or distributed to any retail investors or any other investors that do not fall into the classes of "accredited investors," "expert investors" or "institutional investors," as defined under Section 4A of the SFA. Recipients of this document are to contact JPMSS or JPMCB Singapore in respect of any matters arising from, or in connection with, the document.

Japan: JPMorgan Securities Japan Co., Ltd. and JPMorgan Chase Bank, N.A., Tokyo Branch are regulated by the Financial Services Agency in Japan.

Malaysia: This material is issued and distributed in Malaysia by JPMorgan Securities (Malaysia) Sdn Bhd (18146-X) which is a Participating Organization of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission in Malaysia. **Pakistan:** J. P. Morgan Pakistan Broking (Pvt.) Ltd is a member of the Karachi Stock Exchange and regulated by the Securities and Exchange Commission of Pakistan.

Dubai: JPMorgan Chase Bank, N.A., Dubai Branch is regulated by the Dubai Financial Services Authority (DFSA) and its registered address is Dubai International Financial Centre - Building 3, Level 7, PO Box 506551, Dubai, UAE. **Russia:** CB J.P. Morgan Bank International LLC is regulated by the Central Bank of Russia. **Argentina:** JPMorgan Chase Bank Sucursal Buenos Aires is regulated by Banco Central de la República Argentina ("BCRA"- Central Bank of Argentina) and Comisión Nacional de Valores ("CNV"- Argentinian Securities Commission")

Country and Region Specific Disclosures

U.K. and European Economic Area (EEA): Unless specified to the contrary, issued and approved for distribution in the U.K. and the EEA by JPMS plc. Investment research issued by JPMS plc has been prepared in accordance with JPMS plc's policies for managing conflicts of interest arising as a result of publication and distribution of investment research. Many European regulators require a firm to establish, implement and maintain such a policy. Further

information about J.P. Morgan's conflict of interest policy and a description of the effective internal organisations and administrative arrangements set up for the prevention and avoidance of conflicts of interest is set out at the following link <https://www.jpmorgan.com/jmpdf/1320742677360.pdf>. This report has been issued in the U.K. only to persons of a kind described in Article 19 (5), 38, 47 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons being referred to as "relevant persons"). This document must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is only available to relevant persons and will be engaged in only with relevant persons. In other EEA countries, the report has been issued to persons regarded as professional investors (or equivalent) in their home jurisdiction. **Australia:** This material is issued and distributed by JPMSAL in Australia to "wholesale clients" only. This material does not take into account the specific investment objectives, financial situation or particular needs of the recipient. The recipient of this material must not distribute it to any third party or outside Australia without the prior written consent of JPMSAL. For the purposes of this paragraph the term "wholesale client" has the meaning given in section 761G of the Corporations Act 2001. J.P. Morgan's research coverage universe spans listed securities across the ASX All Ordinaries index, securities listed on offshore markets, unlisted issuers and investment products which Research management deem to be relevant to the investor base from time to time. J.P. Morgan seeks to cover companies of relevance to the domestic and international investor base across all GIC sectors, as well as across a range of market capitalisation sizes. **Germany:** This material is distributed in Germany by J.P. Morgan Securities plc, Frankfurt Branch which is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht. **Korea:** This report may have been edited or contributed to from time to time by affiliates of J.P. Morgan Securities (Far East) Limited, Seoul Branch. **Singapore:** As at the date of this report, JPMSS is a designated market maker for certain structured warrants listed on the Singapore Exchange where the underlying securities may be the securities discussed in this report. Arising from its role as designated market maker for such structured warrants, JPMSS may conduct hedging activities in respect of such underlying securities and hold or have an interest in such underlying securities as a result. The updated list of structured warrants for which JPMSS acts as designated market maker may be found on the website of the Singapore Exchange Limited: <http://www.sgx.com>. In addition, JPMSS and/or its affiliates may also have an interest or holding in any of the securities discussed in this report – please see the Important Disclosures section above. For securities where the holding is 1% or greater, the holding may be found in the Important Disclosures section above. For all other securities mentioned in this report, JPMSS and/or its affiliates may have a holding of less than 1% in such securities and may trade them in ways different from those discussed in this report. Employees of JPMSS and/or its affiliates not involved in the preparation of this report may have investments in the securities (or derivatives of such securities) mentioned in this report and may trade them in ways different from those discussed in this report. **Taiwan:** Research relating to equity securities is issued and distributed in Taiwan by J.P. Morgan Securities (Taiwan) Limited, subject to the license scope and the applicable laws and the regulations in Taiwan. According to Paragraph 2, Article 7-1 of Operational Regulations Governing Securities Firms Recommending Trades in Securities to Customers (as amended or supplemented) and/or other applicable laws or regulations, please note that the recipient of this material is not permitted to engage in any activities in connection with the material which may give rise to conflicts of interests, unless otherwise disclosed in the "Important Disclosures" in this material. **India:** For private circulation only, not for sale. **Pakistan:** For private circulation only, not for sale. **New Zealand:** This material is issued and distributed by JPMSAL in New Zealand only to "wholesale clients" (as defined in the Financial Advisers Act 2008). The recipient of this material must not distribute it to any third party or outside New Zealand without the prior written consent of JPMSAL. **Canada:** This report is distributed in Canada by or on behalf of J.P. Morgan Securities Canada Inc. The information contained herein is not, and under no circumstances is to be construed as an offer to sell securities described herein, or solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. **Dubai:** This report has been distributed to persons regarded as professional clients or market counterparties as defined under the DFSA rules. **Brazil:** Ombudsman J.P. Morgan: 0800-7700847 / ouvidoria.jp.morgan@jpmorgan.com.

General: Additional information is available upon request. Information has been obtained from sources believed to be reliable but JPMorgan Chase & Co. or its affiliates and/or subsidiaries (collectively J.P. Morgan) do not warrant its completeness or accuracy except with respect to any disclosures relative to JPMS and/or its affiliates and the analyst's involvement with the issuer that is the subject of the research. All pricing is indicative as of the close of market for the securities discussed, unless otherwise stated. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. JPMS distributes in the U.S. research published by non-U.S. affiliates and accepts responsibility for its contents. Periodic updates may be provided on companies/industries based on company specific developments or announcements, market conditions or any other publicly available information. Clients should contact analysts and execute transactions through a J.P. Morgan subsidiary or affiliate in their home jurisdiction unless governing law permits otherwise.

"Other Disclosures" last revised September 07, 2019.

Copyright 2019 JPMorgan Chase & Co. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan.